Chemomab Therapeutics Ltd.
CMMB · Pharmaceutical Preparations · 575.4M shares · EDGAR filings ↗
Reference price $2.05 · est. market cap ~$1.2B — last insider purchase, 2026-05-29 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — fibrosis clinical, funded.
Strengths
- Liquidity — current ratio 6.2 (65th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-11.1M)
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
Key metrics
Return on equity
-72.9%
Return on assets
-65.1%
Current ratio
9.1×
Free cash flow
-$11M
Tangible book value
$12M
Cash & investments
$10M
Cash runway
4q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-29 | Mor George Adi | Buy | 4.9K | $2.05 |
| 2026-05-29 | Mor George Adi | Buy | 4.9K | $2.08 |
| 2026-05-29 | Mor George Adi | Other | 32K | — |
| 2026-05-29 | Mor George Adi | Other | 19K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-23 | 2025-12-31 | 0001178913-26-001593 ↗ |
| 20-F | 2025-04-04 | 2024-12-31 | 0001178913-25-001205 ↗ |
| 20-F | 2024-03-28 | 2023-12-31 | 0001178913-24-001124 ↗ |
| 8-K | 2023-06-16 | 2023-06-14 | 0001178913-23-002225 ↗ |
| 8-K | 2023-06-05 | 2023-06-01 | 0001178913-23-002136 ↗ |
| 10-Q | 2023-05-11 | 2023-03-31 | 0001178913-23-001807 ↗ |
| 8-K | 2023-05-11 | 2023-05-11 | 0001178913-23-001809 ↗ |
| 10-K | 2023-03-20 | 2022-12-31 | 0001178913-23-001041 ↗ |
| 8-K | 2023-02-21 | 2022-12-31 | 0001178913-23-000670 ↗ |
| 8-K | 2023-02-21 | 2023-02-21 | 0001178913-23-000679 ↗ |
| 8-K | 2023-01-11 | 2023-01-11 | 0001178913-23-000147 ↗ |
| 8-K | 2023-01-03 | 2023-01-03 | 0001178913-23-000010 ↗ |